MacroGenics, Inc. (NASDAQ: MGNX) presented Phase 2 data from the TAMARACK trial of vobramitamab duocarmazine (vobra duo) in patients with metastatic castration-resistant prostate cancer (mCRPC) at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain.
The TAMARACK trial is a randomized Phase 2 study evaluating the B7-H3 targeting antibody-drug conjugate (ADC) vobramitamab duocarmazine in mCRPC. The poster presentation at ESMO included updated safety and efficacy data with a data cut-off date of July 9, 2024. The primary endpoint of the study was the landmark 6-month radiographic progression-free survival (rPFS).
TAMARACK Trial Design and Endpoints
The TAMARACK trial is designed to assess the efficacy and safety of vobramitamab duocarmazine in mCRPC patients. The primary endpoint is the 6-month landmark rPFS. Secondary endpoints include median rPFS, overall survival, and safety profile. The study enrolled patients with mCRPC who had progressed on prior therapies.
The data presented at ESMO included an updated analysis of the primary endpoint, as well as immature median rPFS data. These data are subject to change as more PFS events accrue over time.
Conference Call Details
MacroGenics anticipates hosting a conference call on Monday, September 16, 2024, at 8:00 a.m. ET to discuss the TAMARACK poster data and provide a general corporate update. The call will be led by Scott Koenig, M.D., Ph.D., President and Chief Executive Officer; Stephen Eck, M.D., Ph.D., Senior Vice President – Clinical Development and Chief Medical Officer; and Jim Karrels, Senior Vice President – Chief Financial Officer.
Details for participating in the conference call and accessing the webcast are available on the MacroGenics website.
